Letter to the Editor
Local injection of micro-dose guselkumab for acrodermatitis continua of Hallopeau after failure of systemic ixekizumab treatment
YuFei Wang,
YuFei Wang
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
These authors contributed equally to this work.
Search for more papers by this author ChaoJing Zhou,
ChaoJing Zhou
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
These authors contributed equally to this work.
Search for more papers by this author YiYun Hou,
YiYun Hou
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
These authors contributed equally to this work.
Search for more papers by this author ZiYue Diao,
ZiYue Diao
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Search for more papers by this author DanDan Chen,
DanDan Chen
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Search for more papers by this author ZhiQiang Yin MD, PhD,
Corresponding Author
ZhiQiang Yin MD, PhD
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Search for more papers by this author
YuFei Wang,
YuFei Wang
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
These authors contributed equally to this work.
Search for more papers by this author ChaoJing Zhou,
ChaoJing Zhou
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
These authors contributed equally to this work.
Search for more papers by this author YiYun Hou,
YiYun Hou
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
These authors contributed equally to this work.
Search for more papers by this author ZiYue Diao,
ZiYue Diao
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Search for more papers by this author DanDan Chen,
DanDan Chen
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Search for more papers by this author ZhiQiang Yin MD, PhD,
Corresponding Author
ZhiQiang Yin MD, PhD
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Search for more papers by this author
First published: 16 January 2024
No abstract is available for this article.
References
- 1Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahé E, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020; 34: 2330–2338.
- 2Smith MP, Ly K, Thibodeaux Q, Bhutani T, Liao W, Beck KM. Acrodermatitis continua of Hallopeau: clinical perspectives. Psoriasis (Auckl). 2019; 9: 65–72.
- 3Xia RY, Liu J, Chen DD, Diao ZY, Gao YM, Yin ZQ. Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis. Indian J Dermatol. 2023; 68: 234.
- 4Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2023; 47: 39–57. https://doi.org/10.1007/s40264-023-01361-w
- 5Xia R, Liu J, Gao Y, Diao ZY, Chen DD, Zhou CJ, et al. Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: a real-world study. Clin Immunol. 2023; 253:109694.
